PACT WITH THE DEVIL: ALEMTUZUMAB THERAPY, IMMUNE SUPPRESSION AND INFECTIOUS COMPLICATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA
Keywords:
CHRONIC LYMPHOCYTIC LEUKEMIA, ALEMTUZUMAB, IMMUNE SUPPRESSION, MYCOBACTERIUM TUBERCULOSIS, ATYPICAL INFECTION.Abstract
Infectious complications are an important cause of hospitalization in patients diagnosed with chronic lymphocytic leukemia. The pathogenesis of infection is complex, involving both disease-induced and treatment-related immune depression. During the last decade, the management of chronic lymphocytic leukemia (CLL) has been redefined by the approval of monoclonal antibody-based treatment, which resulted in improved therapeutic responses. Nonetheless, the profound lymphopenia induced by monoclonal agents was accompanied by increased incidence of infections caused by a new spectrum of opportunistic microorganisms. We report the case of a patient with hypercellular CLL who received Alemtuzumab as first line therapy and obtained a satisfactory therapeutic response, but developed subsequent atypical infectious complications.
References
2. Wadhwa P, Morrison VA. Infectious complications of chronic lymphocytic leukemia. Semin Oncol 2006; 33: 240-249.
3. Ravandi F, O’Brien S. Immune defects in patients with chronic lymphocytic leukemia. Cancer Immunol Immunother 2006; 55: 197-209.
4. Hallek M. Chronic lymphocytic leukemia for the clinician. Annals of Oncology 2011; 22 (Supplement 4): iv54-iv56.
5. Salvana EMT, Robert AS. Infectious complications associated with monoclonal antibodies and related small molecules. Clin Microbiol Rev 2009; 22: 274-290.
6. Hallek M. Therapy of chronic lymphocytic leukaemia. Best Pract Res Cl Ha 2010; 23: 85-96.
7. Morrison AV. Infectious complications of chronic lymphocytic leukaemia: pathogenesis, spectrum of infection, preventive approaches. Best Pract Res Cl Ha 2010; 23: 145-153.
8. Ramsay AG, Evans R, Kiaii S, Svensson L, Hogg N, Gribben JG. Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide. Blood 2013; 121 (14): 2704-2714.
9. Ysebaert L. T cells in CLL: lost in migration. Blood 2013; 121 (14): 2580-2582.
10. Kontoyiannis DP, Georgiadou SP, Wierda WG et al. Impaired bactericidal but not fungicidal activity of polymorphonuclear neutrophils in patients with chronic lymphocytic leukemia. Leuk Lymphoma 2013; 54 (8): doi:10.3109/10428194.2012.750723.
11. Nosari A. Infectious Complications in Chronic Lymphocytic Leukemia. Mediterr J Hematol Infect Dis 2012; 4 (1): doi:10.4084/MJHID.2012.070.
Additional Files
Published
Issue
Section
License
COPYRIGHT
Once an article is accepted for publication, MSJ requests a transfer of copyrights for published articles.
COPYRIGHT TRANSFER FORM FOR
REVISTA MEDICO-CHIRURGICALĂ A SOCIETĂȚII DE MEDICI ȘI NATURALIȘTI DIN IAȘI /
THE MEDICAL-SURGICAL JOURNAL OF THE SOCIETY OF PHYSICIANS AND NATURALISTS FROM IASI
We, the undersigned authors of the manuscript entitled
_____________________________________________________________________________________
_____________________________________________________________________________________
warrant that this manuscript, which is submitted for publication in the REVISTA MEDICO-CHIRURGICALĂ, has not been published and it is not under consideration for publication in another journal.
- we give the consent for publication in the REVISTA MEDICO-CHIRURGICALĂ, in printed and electronic format and we transfer unconditioned and complete the copyright of this manuscript to the REVISTA MEDICO-CHIRURGICALĂ, in the event of its acceptance.
- the manuscript does not break the intellectual property rights of any other person.
- we have read the submitted version of the manuscript and we are fully responsible for the content.
Names and signatures of authors / copyright owners (the following sequence is the authorship of the article):
- ______________________________/_________________________
- ______________________________/_________________________
- ______________________________/_________________________
N.B. All the authors must sign this form